Parkinson’s Disease Laboratory

The Parkinson Disease laboratory has research interest in all aspects of Parkinson’s Disease (PD). 

Our clinical trials

The laboratory's current interests include:

  • Measuring the motor symptoms of PD to assist in their management.  The Parkinsons Kinetigraph (PKG) was developed in this lab and is now being used commercially around the world having received FDA clearance last year.  Much of our research with the PKG relates to ongoing improvements and studies that arise because we can measure objectively.  These include studies on sleep, impulse control disorders and markers for initiating and measuring the effects of advanced therapies.
  • Presymptomatic PD.  We are using various measurements in studies to address whether PD can be detected early.  The aim is to use early detection to better understand the causal mechanisms of disease and develop disease modifying therapies.
  • Factors that control the number of dopamine cells in the brain.  PD affects dopamine cells and we have found that we can regulate the number of dopamine cells in the normal human brain.  We are looking to understand how this is controlled and at the consequences of changing dopamine cells on behaviour and learning.
  • Molecule and cellular process that might underlie PD.   We are understanding how a protein called a-synuclein might influence the function of the lysosome and affect cell function and survival.

Support us

Brain health affects all Australians.
You can support our research by making a donation or a bequest.


Latest breakthroughs, news, events & more.